Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Neuronetics, Inc.

STIMNASDAQ
Healthcare
Medical - Diagnostics & Research
$1.34
$0.00(0.00%)
U.S. Market is Open • 12:59

Neuronetics, Inc. Fundamental Analysis

Neuronetics, Inc. (STIM) shows moderate financial fundamentals with a PE ratio of -1.97, profit margin of -34.27%, and ROE of -1.51%. The company generates $0.1B in annual revenue with moderate year-over-year growth of 4.96%.

Key Strengths

Cash Position39.90%
PEG Ratio-0.07
Current Ratio2.24

Areas of Concern

ROE-1.51%
Operating Margin-29.16%
We analyze STIM's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -162.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-162.7/100

We analyze STIM's fundamental strength across five key dimensions:

Efficiency Score

Weak

STIM struggles to generate sufficient returns from assets.

ROA > 10%
-30.59%

Valuation Score

Excellent

STIM trades at attractive valuation levels.

PE < 25
-1.97
PEG Ratio < 2
-0.07

Growth Score

Weak

STIM faces weak or negative growth trends.

Revenue Growth > 5%
4.96%
EPS Growth > 10%
-31.43%

Financial Health Score

Moderate

STIM shows balanced financial health with some risks.

Debt/Equity < 1
3.32
Current Ratio > 1
2.24

Profitability Score

Weak

STIM struggles to sustain strong margins.

ROE > 15%
-151.29%
Net Margin ≥ 15%
-34.27%
Positive Free Cash Flow
No

Key Financial Metrics

Is STIM Expensive or Cheap?

P/E Ratio

STIM trades at -1.97 times earnings. This suggests potential undervaluation.

-1.97

PEG Ratio

When adjusting for growth, STIM's PEG of -0.07 indicates potential undervaluation.

-0.07

Price to Book

The market values Neuronetics, Inc. at 3.20 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.20

EV/EBITDA

Enterprise value stands at -0.96 times EBITDA. This is generally considered low.

-0.96

How Well Does STIM Make Money?

Net Profit Margin

For every $100 in sales, Neuronetics, Inc. keeps $-34.27 as profit after all expenses.

-34.27%

Operating Margin

Core operations generate -29.16 in profit for every $100 in revenue, before interest and taxes.

-29.16%

ROE

Management delivers $-1.51 in profit for every $100 of shareholder equity.

-1.51%

ROA

Neuronetics, Inc. generates $-30.59 in profit for every $100 in assets, demonstrating efficient asset deployment.

-30.59%

Following the Money - Real Cash Generation

Operating Cash Flow

Neuronetics, Inc. generates limited operating cash flow of $-30.40M, signaling weaker underlying cash strength.

$-30.40M

Free Cash Flow

Neuronetics, Inc. generates weak or negative free cash flow of $-31.09M, restricting financial flexibility.

$-31.09M

FCF Per Share

Each share generates $-0.45 in free cash annually.

$-0.45

FCF Yield

STIM converts -34.18% of its market value into free cash.

-34.18%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-1.97

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.07

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.20

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.69

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

3.32

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.24

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.51

vs 25 benchmark

ROA

Return on assets percentage

-0.31

vs 25 benchmark

ROCE

Return on capital employed

-0.32

vs 25 benchmark

How STIM Stacks Against Its Sector Peers

MetricSTIM ValueSector AveragePerformance
P/E Ratio-1.9729.43 Better (Cheaper)
ROE-151.29%800.00% Weak
Net Margin-34.27%-20145.00% (disorted) Weak
Debt/Equity3.320.30 Weak (High Leverage)
Current Ratio2.244.64 Strong Liquidity
ROA-30.59%-17936.00% (disorted) Weak

STIM outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Neuronetics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-30.77%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

26.19%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

41.10%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ